ALZN Alzamend Neuro, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1677077 · Fiscal year ends 04/30
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-45.7%
TTM EPS YoY-72.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-163.2%
ROA-122.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets32.1%
Debt / equity0.00x
Current ratio—
Interest coverage-1,480.55x
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-30.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-07-31 | 2026Q4*2026-04-30 | 2026Q32026-01-31 | 2026Q22025-10-31 | 2026Q12025-07-31 | 2025Q4*2025-04-30 | 2024Q32025-01-31 | 2024Q22024-10-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.09M | $434,006 | $1.28M | $176,283 | $1.74M | $450,157 | $447,111 | $311,088 |
| SG&A expense | $1.94M | $2.44M | $919,025 | $821,826 | $959,334 | $688,779 | $590,304 | $1.05M |
| Operating income | -$3.03M | -$2.87M | -$2.20M | -$998,109 | -$2.70M | -$1.14M | -$1.04M | -$1.36M |
| Interest expense | $2,005 | $150 | $1,337 | $2,649 | $2,483 | $509 | $2,019 | $3,495 |
| Net income | -$3.03M | -$2.87M | -$2.20M | -$1.00M | -$2.70M | -$1.14M | -$1.04M | -$1.36M |
| EBITDA | -$3.00M | -$2.84M | -$2.17M | -$970,424 | -$2.67M | -$1.13M | -$1.02M | -$1.35M |
| EPS (basic) | -0.68 | — | -0.58 | -0.30 | -1.28 | — | -1.75 | -3.61 |
| EPS (diluted) | -0.68 | — | -0.58 | -0.30 | -1.28 | — | -1.75 | -3.61 |
| Weighted avg. shares (diluted) | 4.48M | — | 3.80M | 3.38M | 2.11M | — | 611,978 | 392,411 |
| Balance sheet | ||||||||
| Cash & equivalents | $7.59M | $710,689 | $2.71M | $4.45M | $5.62M | $3.95M | $3.36M | $4.09M |
| Current assets | $8.25M | $1.76M | $3.70M | $4.72M | $5.93M | $4.18M | $3.95M | $4.77M |
| PP&E, net | $287,181 | $314,866 | $342,551 | $370,236 | $397,921 | $425,606 | $228,291 | $240,976 |
| Total assets | $8.54M | $2.08M | $4.04M | $5.09M | $6.33M | $4.60M | $4.18M | $5.01M |
| Total liabilities | $2.74M | $1.35M | $1.86M | $717,488 | $983,311 | $634,761 | $725,851 | $1.25M |
| Shareholders' equity | $5.80M | $733,211 | $2.20M | $4.37M | $5.34M | $3.97M | $3.45M | $3.75M |
| Shares outstanding | 4.83M | 4.26M | 3.80M | 3.80M | 3.14M | 778,733 | 5.80M | 5.23M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.14M | -$2.80M | -$1.74M | -$1.17M | -$2.36M | -$688,705 | -$1.42M | -$3.40M |
| Investing cash flow | — | — | — | — | — | -$210,000 | $0 | $0 |
| Financing cash flow | $8.02M | $794,844 | $0 | $0 | $4.04M | $1.49M | $688,700 | $6.30M |
| Depreciation & amortization | $27,685 | $27,685 | $27,685 | $27,685 | $27,685 | $12,685 | $12,685 | $12,685 |
| Stock-based compensation | $77,199 | $623,811 | $9,300 | $31,514 | $42,902 | $81,277 | $81,277 | $81,277 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.